Cori Disease (Type III)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Cori disease (glycogen storage disease type III) is an inherited inability to fully break down glycogen, the stored form of glucose. Abnormal glycogen collects in the liver, causing an enlarged liver and low blood glucose during fasting. The common type IIIa also affects skeletal muscle and sometimes heart function; type IIIb primarily affects the liver. Symptoms often begin in childhood, but muscle or liver complications can become more apparent later. Treatment centers on a carefully planned diet and ongoing metabolic, liver and muscle monitoring.
Clinical Definition
Cori disease (GSD III) is an autosomal recessive AGL-related glycogen debranching enzyme deficiency. The enzyme has 4-alpha-glucanotransferase and amylo-alpha-1,6-glucosidase activities. Incomplete cytosolic glycogen breakdown leaves short outer branches (limit dextrin). Typical findings are hepatomegaly, ketotic fasting hypoglycemia and hyperlipidemia. Gluconeogenesis remains intact, so fasting lactate is usually normal, unlike GSD I; lactate can rise after meals. IIIa (~85%) involves liver and skeletal/cardiac muscle; IIIb (~15%) is hepatic. Hypoglycemia can be severe, and IIIa myopathy or cardiomyopathy must not be dismissed as uniformly mild.
Inciting Event
Symptoms often become apparent during periods of fasting or illness when glycogenolysis is required.
Metabolic stress such as infection or prolonged fasting triggers hypoglycemia and muscle symptoms.
Initial presentation may follow weaning from frequent feeding in infancy.
Latency Period
Hepatic manifestations commonly emerge in infancy or early childhood, with variable age at recognition.
The genetic enzyme defect is present from birth; presentation depends on feeding intervals, metabolic demand and organ involvement, rather than a fixed incubation period.
Hepatomegaly and fasting intolerance may improve with age, while myopathy, cardiomyopathy or liver fibrosis can persist or progress.
Diagnostic Delay
Misdiagnosis as other glycogen storage diseases due to overlapping clinical features.
Lack of awareness of debranching enzyme deficiency leads to delayed enzyme or genetic testing.
Symptoms such as hypoglycemia and hepatomegaly may be attributed to more common metabolic or hepatic disorders.
Muscle symptoms may be mistaken for primary myopathies delaying correct diagnosis.
Clinical Presentation
Signs & Symptoms
Fasting hypoglycemia with symptoms like irritability and sweating.
Hepatomegaly causing abdominal distension.
Muscle weakness and hypotonia leading to delayed motor milestones.
Growth delay and failure to thrive in infancy.
Hyperlipidemia and elevated transaminases accompany hepatic disease and can be substantial. CK may be elevated in IIIa.
History of Present Illness
Presentation includes fasting hypoglycemia, hepatomegaly, and growth retardation in infancy.
In IIIa, muscle weakness may be subtle in childhood and become more prominent in adulthood; absence of early weakness does not exclude muscle involvement.
Episodes of lethargy, irritability, and seizures may occur during hypoglycemic crises.
Hepatomegaly and elevated transaminases may improve over time, but improvement does not eliminate the risk of liver fibrosis or cirrhosis.
Some patients develop cardiomyopathy or muscle cramps with exertion.
Past Medical History
History of recurrent hypoglycemia or metabolic crises during infancy or early childhood.
Previous episodes of hepatomegaly or elevated liver enzymes without clear etiology.
Ask about exercise intolerance, motor delay, weakness or a previous abnormal cardiac evaluation, which may identify IIIa involvement.
Other illnesses can coexist; their absence is not a diagnostic criterion for GSD III.
Family History
Siblings or close relatives with glycogen storage diseases or unexplained hypoglycemia.
Consanguineous parents increase likelihood of autosomal recessive inheritance.
Family history of early childhood liver disease or muscle weakness may be present.
Known carriers of mutations in the AGL gene within the family.
Physical Exam Findings
Hepatomegaly due to glycogen accumulation in the liver is a hallmark finding.
Muscle weakness and hypotonia may be observed from glycogen buildup in skeletal muscle.
Growth retardation is common due to chronic metabolic disturbances.
Hypoglycemia signs such as diaphoresis and pallor may be present during fasting.
Diagnostic Workup
Diagnostic Criteria
Establish GSD III by identifying biallelic pathogenic/likely pathogenic AGL variants in a compatible clinical setting. If genetic testing is inconclusive, specialized debranching enzyme activity testing in blood cells, cultured fibroblasts or selected tissue can help. Liver or muscle biopsy is not routinely required when molecular diagnosis is established. A variant of uncertain significance alone is not confirmation. Hepatomegaly, ketotic fasting hypoglycemia, elevated transaminases and possible IIIa myopathy support the workup.
Pathophysiology
Key Mechanisms
The AGL debranching enzyme transfers a short glucose chain through its transferase activity and removes the remaining alpha-1,6-linked branch-point glucose through its glucosidase activity. Deficiency leaves incompletely degraded glycogen.
Cytosolic limit-dextrin accumulation injures hepatocytes and, in IIIa, skeletal and cardiac muscle cells. This differs from lysosomal glycogen storage in Pompe disease.
Limited glycogenolysis causes fasting intolerance, but gluconeogenesis is preserved. Protein-derived glucogenic amino acids can support glucose production; fasting fat oxidation produces ketones.
Secondary hepatomegaly arises from glycogen and fat accumulation in hepatocytes.
In IIIa, glycogen accumulation and impaired muscle energy availability contribute to weakness, exercise intolerance and possible cardiomyopathy.
| Involvement | Details |
|---|---|
| Organs | Liver is the main organ involved, showing hepatomegaly and impaired glycogenolysis due to defective debranching enzyme activity. |
Skeletal muscle and heart are involved in IIIa to varying degrees; IIIb is the hepatic form. | |
| Tissues | Liver tissue is critically involved as abnormal glycogen accumulation causes hepatomegaly and impaired glucose release. |
In IIIa, glycogen accumulation affects skeletal and cardiac muscle tissue; muscle involvement is not a defining feature of IIIb. | |
| Cells | Hepatocytes are the primary cells affected in Cori disease, where defective glycogen debranching enzyme activity leads to abnormal glycogen accumulation. |
Skeletal myocytes and cardiomyocytes accumulate abnormal glycogen in IIIa, contributing to myopathy and cardiac hypertrophy. | |
| Chemical Mediators | Glycogen debranching enzyme deficiency caused by mutations in the AGL gene leads to accumulation of abnormal glycogen with short outer branches in Cori disease. |
Treatments
Pharmacological Treatments
No disease-specific pharmacological treatment is listed for this topic.
Non-pharmacological Treatments
Use frequent meals and a specialist-designed high-protein diet, with carbohydrate tailored to maintain glucose without excess intake. Protein supports intact gluconeogenesis; indiscriminate high-carbohydrate feeding can worsen glycogen storage and IIIa cardiac disease.
Uncooked cornstarch can provide slowly digested carbohydrate when age and tolerance are appropriate, often toward the end of the first year. Adjust amount and timing to glucose/ketone measurements; infants need an age-appropriate feeding plan.
Monitor glucose and ketones, growth, lipids, liver function/imaging, CK and muscle function, with ECG/echocardiographic surveillance for cardiac involvement. Dietary treatment does not guarantee prevention of long-term complications.
Prevention
Pharmacological Prevention
Prevention primarily uses medical nutrition therapy, including individualized cornstarch when appropriate; cornstarch does not restore the missing enzyme.
Glucose polymers are not automatically slow-release substitutes for uncooked cornstarch. A metabolic dietitian selects feeds and emergency carbohydrate sources according to age, activity and measured response.
Non-pharmacological Prevention
Avoid prolonged fasting and provide a written sick-day and perioperative plan. Inability to maintain enteral intake requires urgent medical assessment and glucose support.
Continue liver, muscle and cardiac surveillance even if fasting hypoglycemia improves with age. Test at-risk siblings early when familial variants are known.
Provide metabolic-dietitian follow-up to balance protein, carbohydrate, total calories and micronutrients; avoid both undertreatment and overfeeding.
Outcome & Complications
Complications
Severe hypoglycemia leading to seizures or neurological damage if untreated.
Liver fibrosis can progress to cirrhosis; adenomas and, less commonly, hepatocellular carcinoma are recognized complications requiring surveillance.
Muscle wasting and weakness impairing mobility.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Cori Disease (Type III) versus Von Gierke Disease (Type I Glycogen Storage Disease)
Cori Disease (Type III) | Von Gierke Disease (Type I Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance | Autosomal recessive inheritance |
Ketotic fasting hypoglycemia; lactate and uric acid usually normal, with CK elevation possible in IIIa | Typically more severe fasting hypoglycemia with elevated lactate, uric acid and lipids |
Biallelic pathogenic/likely pathogenic AGL variants; deficient cytosolic debranching activity if enzyme confirmation is needed | Biallelic G6PC1 variants in Ia or SLC37A4 variants in Ib; defects of the glucose-6-phosphatase system |
Hepatic fasting intolerance often improves with age; IIIa muscle/cardiac disease and liver fibrosis can progress | Early hepatic/renal metabolic disease; primary skeletal myopathy is not characteristic, and Ib also causes neutropenia/infection risk |
Cori Disease (Type III) versus Pompe Disease (Type II Glycogen Storage Disease)
Cori Disease (Type III) | Pompe Disease (Type II Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance | Autosomal recessive inheritance |
CK often elevated in IIIa; cardiac hypertrophy or cardiomyopathy can occur alongside hepatic hypoglycemia | CK may be elevated; hypertrophic cardiomyopathy is typical of infantile-onset Pompe, not all late-onset disease |
Biallelic pathogenic/likely pathogenic AGL variants; deficient cytosolic debranching activity if enzyme confirmation is needed | Deficient lysosomal acid alpha-glucosidase and/or biallelic pathogenic GAA variants |
Hepatomegaly and ketotic fasting intolerance with variable IIIa skeletal/cardiac disease | Infantile disease: hypotonia and cardiomyopathy; late-onset disease: predominantly progressive skeletal and respiratory weakness |
Cori Disease (Type III) versus McArdle Disease (Type V Glycogen Storage Disease)
Cori Disease (Type III) | McArdle Disease (Type V Glycogen Storage Disease) |
|---|---|
Autosomal recessive inheritance | Autosomal recessive inheritance |
Hepatic metabolic abnormalities plus possible persistent CK elevation in IIIa | CK commonly elevated even at rest; exercise-induced rhabdomyolysis can cause myoglobinuria |
Biallelic pathogenic/likely pathogenic AGL variants; deficient cytosolic debranching activity if enzyme confirmation is needed | Biallelic pathogenic PYGM variants or deficient muscle glycogen phosphorylase activity |
Hepatic fasting intolerance and hepatomegaly; IIIa can also produce progressive myopathy | Exercise-induced cramps and intolerance with a characteristic second wind; primary hepatic fasting hypoglycemia is not typical |
Cori Disease (Type III) versus Fanconi-Bickel Syndrome
Cori Disease (Type III) | Fanconi-Bickel Syndrome |
|---|---|
Autosomal recessive inheritance | Autosomal recessive inheritance |
Ketotic fasting intolerance; generalized proximal tubular dysfunction is not characteristic | Proximal tubular losses including glucose, amino acids and phosphate; fasting hypoglycemia and postprandial hyperglycemia |
Biallelic pathogenic/likely pathogenic AGL variants; deficient cytosolic debranching activity if enzyme confirmation is needed | Biallelic pathogenic SLC2A2 variants affecting the GLUT2 transporter |
Hepatomegaly with variable IIIa muscle/cardiac disease; renal Fanconi syndrome is not a defining feature | Hepatomegaly, growth failure, renal Fanconi syndrome, proximal renal tubular acidosis and hypophosphatemic rickets |